3T Biosciences

The J.P. Morgan Healthcare Conference in San Francisco has yet to kick off but Boehringer Ingelheim GmbH has already inked three deals this January, the latest being a link-up with Kyowa Kirin Co.,

As sales of Jardiance continue to soar, Boehringer Ingelheim GmbH is making good use of the revenues from the blockbuster to advance its pipeline, especially in the oncology space. The family-owned

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu

San Francisco start-up 3T Biosciences came out of stealth mode on 25 August with $40m in new venture capital from a series A round led by Westlake Village BioPartners with participation from Lightsp